Trial Profile
Characterising the vedolizumab associated Spondyloarthritides/entheseal flares in patients with Inflammatory Bowel Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 10 Sep 2018 Results characterizing the Vedolizumab -associated Spondyloarthritides or entheseal flares published in the Rheumatology.
- 17 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism